Largest U.S. Prospective Clinical Trial Ever Conducted Demonstrated High Compliance with the Flexitouch® System and Significant Improvements Across Study Endpoints Largest U.S. Prospective Clinical Trial Ever Conducted Demonstrated High Compliance with the Flexitouch® System and Significant Improvements Across Study Endpoints
MINNEAPOLIS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the second quarter ended June 30, 2024.
MINNEAPOLIS, July 22, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that second quarter of fiscal year 2024 financial results will be released after the market closes on Monday, August 5, 2024.
The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones.
MINNEAPOLIS, May 21, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the William Blair 44th Annual Growth Stock Conference, which is being held at the Loews Hotel in Chicago, IL from June 4th - 6th. M...
Tactile Systems Technology, Inc. (NASDAQ:TCMD ) Q1 2024 Earnings Conference Call May 6, 2024 5:00 PM ET Company Participants Sam Bentzinger – Investor Relations-Gilmartin Group LLC Dan Reuvers – President and Chief Executive Officer Elaine Birkemeyer – Chief Financial Officer Conference Call Participants Adam Maeder – Piper Sandler Margaret Kaczor – William Blair Suraj Kalia – Oppenheimer & Com...
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Summary: Total revenue increased 4% year-over-year to $61.1 million Lymphedema product ...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.